Utah Medical Products projects 2026 sales to decline 10-13% compared to 2025
Company expects 2026 litigation expenses to be less than $1.6 mln
Company says substantial uncertainty remains regarding sales development for 2026
Overview
US medical device maker's Q2 revenue fell 14% yr/yr due to loss of major customers
Q2 diluted EPS declined 10% yr/yr as new sales failed to offset lost business
Company saw higher litigation costs and slight contraction in gross margin
Key details
Metric
Actual
Q2 Sales
$8.53 mln
Q2 EPS
$0.84
Q2 Net Income
$2.69 mln
Result drivers
Loss of major customers - Co said lower sales were mainly due to lack of sales to its two previously largest customers, which accounted for most of the revenue decline
Slow new sales - Sales to new biopharma OEM customers were slower to develop than expected, with only $211 in new sales in 1H 2026
UTMD•
